AlphaQuest LLC Increases Stake in Insulet Co. (NASDAQ:PODD)

AlphaQuest LLC boosted its position in Insulet Co. (NASDAQ:PODD - Free Report) by 12,800.0% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,290 shares of the medical instruments supplier's stock after purchasing an additional 1,280 shares during the period. AlphaQuest LLC's holdings in Insulet were worth $337,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of PODD. Janney Montgomery Scott LLC increased its stake in shares of Insulet by 7.5% in the third quarter. Janney Montgomery Scott LLC now owns 5,661 shares of the medical instruments supplier's stock worth $1,318,000 after purchasing an additional 394 shares in the last quarter. Venturi Wealth Management LLC boosted its holdings in Insulet by 633.3% in the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier's stock worth $36,000 after buying an additional 133 shares during the period. GSA Capital Partners LLP bought a new position in Insulet in the 3rd quarter worth approximately $1,017,000. Sumitomo Mitsui Trust Group Inc. grew its stake in Insulet by 3.5% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 156,326 shares of the medical instruments supplier's stock valued at $36,385,000 after buying an additional 5,226 shares in the last quarter. Finally, Prime Capital Investment Advisors LLC bought a new stake in Insulet during the 3rd quarter valued at $265,000.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on PODD. JPMorgan Chase & Co. lifted their price target on Insulet from $280.00 to $330.00 and gave the company an "overweight" rating in a research report on Thursday, December 12th. TD Cowen lifted their target price on Insulet from $264.00 to $324.00 and gave the company a "buy" rating in a report on Friday, January 3rd. StockNews.com downgraded shares of Insulet from a "buy" rating to a "hold" rating in a report on Tuesday, March 4th. Citigroup raised their price objective on shares of Insulet from $310.00 to $355.00 and gave the company a "buy" rating in a research report on Friday, February 21st. Finally, Raymond James reissued an "outperform" rating and issued a $328.00 price target (up from $294.00) on shares of Insulet in a report on Friday, February 21st. Four analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $292.06.

Remove Ads

Insider Activity

In related news, EVP Eric Benjamin sold 12,394 shares of the firm's stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total value of $3,470,320.00. Following the sale, the executive vice president now directly owns 11,383 shares of the company's stock, valued at $3,187,240. This trade represents a 52.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 0.47% of the company's stock.

Insulet Trading Down 0.4 %

NASDAQ:PODD traded down $1.16 during trading hours on Tuesday, reaching $260.47. The company's stock had a trading volume of 738,469 shares, compared to its average volume of 690,578. The firm has a 50-day simple moving average of $272.40 and a 200-day simple moving average of $255.72. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. Insulet Co. has a 1 year low of $160.19 and a 1 year high of $289.46. The firm has a market capitalization of $18.29 billion, a price-to-earnings ratio of 44.99, a PEG ratio of 3.62 and a beta of 1.29.

Insulet (NASDAQ:PODD - Get Free Report) last released its earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, beating analysts' consensus estimates of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The company had revenue of $597.50 million during the quarter, compared to analyst estimates of $582.02 million. Research analysts expect that Insulet Co. will post 3.92 EPS for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.